...Switzerland to treat AA amyloidosis. Bellus granted exclusive, worldwide rights to Kiacta to Auven (formerly Celtic Therapeutics...

...Mount Sinai granted private equity firm Auven Therapeutics (formerly Celtic Therapeutics) exclusive, worldwide rights to develop and...

...were transferred to a holding company 75% owned by private equity firm Auven Therapeutics (formerly Celtic Therapeutics...

...granted exclusive, worldwide rights to Kiacta to Celtic Therapeutics Holdings. Bellus Health Inc. (TSX:BLU), Laval, Quebec Celtic Therapeutics...

...MedImmune and ADC Therapeutics will share costs and profits. Private equity firm Auven Therapeutics (formerly Celtic Therapeutics...

...be transferred to a holding company 75% owned by private equity firm Auven Therapeutics (formerly Celtic Therapeutics...

...profits. Both Spirogen and ADC Therapeutics were launched by private equity firm Auven Therapeutics (formerly Celtic Therapeutics...

...granted exclusive, worldwide rights to Kiacta to Celtic Therapeutics Holdings. Bellus Health Inc. (TSX:BLU), Laval, Quebec Celtic Therapeutics...

...Private equity firm Celtic Therapeutics Management LLLP changed its name to Auven Therapeutics "to avoid confusion related to other...
...to other Celtic entities." The firm also changed the name of its private equity fund Celtic Therapeutics...

...who previously was SVP and CFO, also joined Safeguard's board. PE tracks Beth Hecht joined Celtic Therapeutics...